Fujifilm Holdings Corp. Price and EPS Surprise Fujifilm Holdings Corp. price-eps-surprise | Fujifilm Holdings Corp. Quote   Let’s see how things are shaping up for the upcoming announcement.Factors to ConsiderFUJIFILM is expected to have benefited from the robust performance of the Healthcare business in the to-be-reported quarter, backed by acquisitions carried out over the trailing 12-months.Moreover, the company’s heavy investments in gene therapy, one of the key growth areas in the Bio Contract Development and Manufacturing Organization business and the regenerative medicine business, have expanded growth opportunities in healthcare.Notably, in the last reported quarter, Healthcare revenues grew 6.7% at constant currency (cc) on a year-over-year basis to ¥126.3 billion.Furthermore, investments to expand facilities for the development, manufacture and quality assurance of cutting-edge semiconductor materials are expected to have aided the top line.However, a slowing economy in China due to lower consumption growth and weakness in the Imaging Solutions and Documents Solutions businesses is expected to have dampened the company’s revenues.Notably, in the last reported quarter, Imaging Solutions revenues were ¥79.5 billion, down 5.6% from the year-ago quarter at cc.They deem these tickers “Most Likely for Early Price Pops.”Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.7% per year.